Sign in

    Robert Finke

    Vice President and former Biotech Equity Research Analyst at Guggenheim Securities

    Robert Finke is a Vice President and former Biotech Equity Research Analyst at Guggenheim Securities, where he specialized in covering public biotechnology companies, including names like BioMarin Pharmaceutical, and contributed detailed research and financial analysis across the life sciences sector. During his tenure at Guggenheim through 2024, he built a reputation for in-depth company coverage on key industry players, participating in analyst calls and leveraging a strong academic background with a Pharm.D. magna cum laude from the University of Rhode Island and an M.B.A. from Indiana University. His career began in the biotechnology financial research space, and he moved to Great Point Partners as an analyst in late 2024. Finke holds robust professional credentials in finance and life sciences, reflecting both advanced university honors and sector experience.

    Robert Finke's questions to Sarepta Therapeutics (SRPT) leadership

    Robert Finke's questions to Sarepta Therapeutics (SRPT) leadership • Q2 2024

    Question

    Robert Finke asked if manufacturing capacity is anticipated to be a gating factor at any point between now and reaching peak sales for ELEVIDYS.

    Answer

    CEO Douglas Ingram stated definitively that the company does not envision manufacturing being a bottleneck for the next few years. He added that by the time it could become a rate-limiter, the company hopes to be using its suspension-based manufacturing process, which should not have limitations. He concluded they are in a very good position from a supply perspective.

    Ask Fintool Equity Research AI